Results 251 to 260 of about 12,943 (270)

Pseudotyped Viruses for Marburgvirus and Ebolavirus.

Advances in Experimental Medicine and Biology, 2023
Marburg virus (MARV) and Ebola virus (EBOV) of the Filoviridae family are the most lethal viruses in terms of mortality rate. However, the development of antiviral treatment is hampered by the requirement for biosafety level-4 (BSL-4) containment. The establishment of BSL-2 pseudotyped viruses can provide important tools for the study of filoviruses ...
Li Zhang, Shoutao Liu, Youchun Wang
semanticscholar   +3 more sources

A highly attenuated pan-filovirus VesiculoVax vaccine rapidly protects nonhuman primates against Marburg virus and three species of Ebolavirus.

Journal of Infectious Diseases, 2023
BACKGROUND The family Filoviridae consists of several virus members known to cause significant mortality and disease in humans. Among these, Ebola virus (EBOV), Marburg virus (MARV), Sudan virus (SUDV), and Bundibugyo virus (BDBV) are considered the ...
Courtney Woolsey, V. Borisevich, K. Agans, Rachel O'Toole, Karla A. Fenton, Mack B Harrison, A. Prasad, D. Deer, Cheryl S. Gerardi, Nneka Morrison, R. Cross, J. Eldridge, Demetrius Matassov, T. Geisbert   +13 more
semanticscholar   +1 more source

Reston Ebolavirus in Macaques

2020
Prior to the discovery of the Reston ebolavirus (RESTV) in 1989, filoviruses were thought to be present only in Africa. The virus was discovered in a quarantine facility in Reston, Virginia, USA, following the deaths of imported cynomolgus macaques (Macaca fascicularis) from the Philippines displaying severe haemorrhagic disease.
Catalino S. Demetria, Shuetsu Fukushi, Ina Smith   +2 more
openaire   +2 more sources

Immune Evasion in Ebolavirus Infections

Viral Immunology, 2015
Ebola virus (EBOV) infects humans as well as several animal species. It can lead to a highly lethal disease, with mortality rates approaching 90% in primates. Recent advances have deepened our understanding of how this virus is able to prevent the development of protective immune responses.
Gary P. Kobinger, Jonathan Audet
openaire   +3 more sources

In silico analyses and experimental validation of the MHC class-I restricted epitopes of Ebolavirus GP.

International Immunology, 2022
Ebolavirus (EBOV) causes an extremely high mortality and prevalence disease called Ebola virus disease (EVD). There is only one glycoprotein (GP) on the virus particle surface, which mediates entry into the host cell.
Yang Liu, Baozeng Sun, Jiawei Wang, Hao Sun, Zhen-hua Lu, Longyu Chen, Mingfu Lan, Jiahao Xu, Jingyu Pan, Jingqi Shi, Yuanjie Sun, Xi-yang Zhang, Jing Wang, Dongbo Jiang, Kun Yang   +14 more
semanticscholar   +1 more source

Peptides for Anti-Ebolavirus Vaccines

Current Drug Discovery Technologies, 2016
Two main factors can affect the development of ebolavirus immunotherapeutics: the vast peptide commonality between ebolavirus and human proteins, and the high rate of spontaneous mutation of ebolavirus within its human host. Indeed, the viral versus human peptide overlap may represent a relevant source of autoimmune crossreactions following vaccination,
openaire   +3 more sources

Ebolavirus: An Overview of Molecular and Clinical Pathogenesis

2017
Ebolaviruses cause severe, often fatal hemorrhagic fever in Central, East, and West Africa. Until recently, they have been viewed as rare but highly pathogenic infections with regional, but limited, global public health impact. This view has changed with the emergence of the first epidemic of Ebola hemorrhagic fever in West Africa.
Heinz Feldmann, Veronica Vine, Dana P. Scott   +2 more
openaire   +3 more sources